-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
It was learned on January 17 that VV116, the only small molecule drug for the treatment of COVID-19 that has been approved for clinical trials in China, will start its NDA application as soon as it passes the clinical trials within the year
.
Preclinical pharmacodynamic studies have shown that VV116 has significant inhibitory activity against the original and variant strains of the new coronavirus, such as delta virus, in vitro
According to public information, at present, there are three main technical routes for the research and development of new crown treatment drugs: drugs that block the entry of viruses into cells (mostly antibody drugs), drugs that inhibit virus replication (mostly small molecule drugs), and drugs that regulate the human immune system.
(Chinese herbal medicine, etc.
)
.
VV116 is currently the only small molecule drug for the treatment of COVID-19 that has been approved for clinical trials in China (there are already 2 small molecules abroad: Merck's monupavir and Pfizer's paciclovir have been approved for marketing)
VV116 was jointly developed by Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Wuhan Institute of Virology, Chinese Academy of Sciences, Xinjiang Institute of Physical and Chemical Technology, Chinese Academy of Sciences, and Central Asia Drug Research and Development Center, Chinese Academy of Sciences, and was approved for clinical trials on November 2, 2021
Reference source: Financial Associated Press, The Paper
